En prospektiv observationsstudie om tidig debuterande gastrointestinal cancer: Från tumörkarakteristika till patienters livsstilsvanor (YOGICO)
En prospektiv observationsstudie om tidigdebuterande gastrointestinal cancer: Från tumörkaraktäristik till patientens livsstilsvanor - YOGICO-studien
The YOGICO study aims to characterize the distinctive features of EoGI cancer through a holistic approach that integrates clinical and demographic data, tumor biological characteristics, and patient lifestyle habits
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is an observational, prospective multicenter study to characterize newly diagnosed EoGI cancer patients from a holistic approach, covering aspects from tumor features to patient lifestyle habits. Since this is a prospective observational study, participation does not alter any cancer treatments that patients will undergo after their cancer diagnosis, as per best clinical practice at each participating center. The number of patients included in the study will range from 150 to 200, enrolled in national centers located in northern Italy, as well as in diverse hospital settings (e.g., small vs. large hospitals).
Studietyp
Inskrivning (Beräknad)
Kontakter och platser
Studiekontakt
- Namn: Ilaria Bernardini, MD
- Telefonnummer: +39 059659294
- E-post: i.bernardini@ausl.mo.it
Studieorter
-
-
BO
-
Bologna, BO, Italien
- Har inte rekryterat ännu
- Oncologia, Ospedale Sant'Orsola
-
Kontakt:
- Karim Rihawi, MD
-
-
FC
-
Meldola, FC, Italien
- Aktiv, inte rekryterande
- Istituto Romagnolo per lo studio dei tumori "Dino Amadori", IRCCS IRST
-
-
MO
-
Carpi, MO, Italien
- Rekrytering
- Oncologia di Prossimità, Ospedale di Carpi e DHO Mirandola, Ausl Modena
-
Kontakt:
- Claudia Mucciarini, MD
-
Modena, MO, Italien
- Aktiv, inte rekryterande
- Centro Oncologico Modenese, Azienda Policlinico Universitaria di Modena
-
Sassuolo, MO, Italien
- Rekrytering
- Oncologia Area Sud Ausl Modena
-
Kontakt:
- Teresa Zielli, MD
-
-
Minnesota
-
Mantua, Minnesota, Italien
- Aktiv, inte rekryterande
- Oncologia Ospedale Carlo Poma di Mantova
-
-
PC
-
Piacenza, PC, Italien
- Aktiv, inte rekryterande
- Oncologia Medica, AUSL Piacenza
-
-
PR
-
Parma, PR, Italien
- Rekrytering
- Oncologia, Azienda Ospedaliero Universitaria di Parma
-
Kontakt:
- Annalisa Gilli, MD
-
-
RE
-
Reggio Emilia, RE, Italien
- Rekrytering
- Oncologia Medica, CORE Azienda USL-IRCCS Reggio Emilia
-
Kontakt:
- Francesco Caputo, MD
-
-
RN
-
Rimini, RN, Italien
- Rekrytering
- Oncologia, Ospedale di Rimini
-
Kontakt:
- Francesca Fabbri, MD
-
-
VA
-
Varese, VA, Italien
- Har inte rekryterat ännu
- Oncologia, ASST SETTE LAGHI, Ospedale di Circolo
-
Kontakt:
- Michele Ghidini, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients will be selected and recruited during routine medical appointments by specialized medical oncologists at the participating cancer center. Patients will be enrolled consecutively based on inclusion and exclusion criteria
Beskrivning
Inclusion Criteria:
- Provide a signed and dated informed consent form (ICF)
- Willing to comply with all study procedures and be available for the duration of the study
- Male or female, aged 18-49 years old at time of EoGI cancer diagnosis
- Patients with newly diagnosed early-onset gastrointestinal cancer histologically confirmed: colorectal, gastroesophageal and pancreatic tumor site, regardless of histological type
- Any disease stage, performance status, and type of treatment, including experimental therapies and supportive care
- Previous or concomitant malignancies are allowed provided they do not involve the gastrointestinal tract
Exclusion Criteria:
- Cognitive, linguistic, or physical barriers that prevent a detailed reconstruction of the patient's personal medical history including past lifestyle habits
- Having previously received any treatments directed at the newly diagnosed EOGI cancer (i.e., at the time of inclusion, the patient has not yet started any type of treatment, excluding surgery)
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
EoGI-kräftpatienter nyligen diagnostiserade
|
to characterize the distinctive features of EO-GI cancer through a comprehensive approach that considers clinical and demographic factors, tumor features, and patient lifestyle habits, in a real-world Italian settings, mainly located in Northern Italy |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Primary outcome
Tidsram: One year from the enrollment
|
Describe clinical and tumor features of newly diagnosed EoGI cancer patients in a real-world Italian setting. |
One year from the enrollment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Secondary outcome measure
Tidsram: Six and twelve months follow-up
|
EoGI cancer type of treatment at diagnosis (chemotherapy, immunotherapy, targeted therapy, surgery, radiotherapy or best supportive care); progression of disease (if any) and survival status at 6 and 12 months follow-up. |
Six and twelve months follow-up
|
|
Secondary Outcome
Tidsram: Two years
|
Incidence and prevalence of newly diagnosed EoGI cancer at each participating site during the study accrual time period |
Two years
|
|
Secondary Outcome
Tidsram: One years from enrollment
|
Description of patients' lifetime exposure to behavioral and cancer-related risk factors |
One years from enrollment
|
|
Secondary Outcome
Tidsram: One years from enrollment
|
Identify associations between past lifestyle habits (diet, physical activity, smoking, alcohol consumption,) and tumor-related features (stage, histology, anatomical site, and molecular markers) in EoGI cancer patients |
One years from enrollment
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- GOIRC-03-2025
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .